Also known as Ala-Glu-Asp-Pro · AEDP
A Khavinson short peptide bioregulator (Ala-Glu-Asp-Pro) studied for cerebral-cortex and peripheral-nerve regeneration.
Research refreshed
4 residues · single-letter amino-acid sequence
Cortagen is one of the Khavinson short-peptide bioregulators — a synthetic tetrapeptide, Ala-Glu-Asp-Pro, developed in Russia and associated with the cerebral cortex and nervous tissue. Like the other bioregulators in this family, it is proposed to act as a tissue-specific, gene-regulatory signal, and it has been studied in Russian research for peripheral-nerve repair and CNS function. It is a research peptide, and its evidence base is largely from one research school and is not FDA-approved.
Cortagen belongs to the family of short peptide bioregulators developed by Khavinson and colleagues, each linked to a particular tissue — Cortagen to the cerebral cortex and nervous system. The governing idea is that very short peptides act as regulatory signals that normalize gene expression and function in their target tissue, and this catalog profiles several members (Cartalax, Pinealon, Cerluten, and others) on the same premise.
Research on Cortagen, mainly from Russian groups, has examined peripheral-nerve regeneration and cortical function. As with the family generally, independent replication is limited and the mechanism remains a hypothesis rather than an established pathway. It is a research compound and is not FDA-approved; this page is a research and educational reference.
Proposed tissue-specific gene-regulatory activity (the Khavinson bioregulator hypothesis): short peptides binding DNA/chromatin to modulate expression in cortical and neural tissue. Mechanism is hypothesized more than proven in independent work.
Behind every vial of Cortagen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cortagen, specifically, is brought into being.
Cortagen begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Cortagen means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Cortagen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Cortagen proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cortagen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A linear tetrapeptide (Ala-Glu-Asp-Pro) — trivial to synthesize by solid-phase methods. Making it is easy; the real question is identity, because a 4-mer is cheap to produce under any label. A certificate should show mass spectrometry and HPLC assay confirming the exact sequence and purity.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Cortagen, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A Khavinson short-peptide bioregulator (Ala-Glu-Asp-Pro) associated with the cerebral cortex and nervous tissue, studied for nerve regeneration and cortical function.
Through the bioregulator hypothesis — short peptides acting as tissue-specific, gene-regulatory signals. The mechanism is hypothesized more than independently proven.
Limited and largely from one research tradition, with little independent replication. Treat it as an early research compound.
No — it is a research peptide, not FDA-approved. This page is a research and educational reference.
Synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) studied for telomerase activity, circadian regulation, and rodent lifespan endpoints.
ViewThymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
ViewA synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.